Wire · opportunities
FDA expands TearCare System indication for MG function improvement
◆ Sectors
Medtech
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 22 August 2026 · Fusion42 review
The FDA expanded the indication for the TearCare System, allowing it to be marketed as a therapy that improves meibomian gland function in adults with evaporative dry eye disease due to meibomian gland dysfunction, beyond merely applying localized heat therapy.
This Wire brief sits within Fusion42's coverage of Medtech.
◆ ◆ The Wire takeaway
You have a new route to differentiate your dry eye therapy with proven gland function improvement. This clearance opens a clearer marketing claim that can help you win clinician trust and patient adoption.
◆ Coverage
1 source · 22 Aug 2026
◆ Related on Wire
◆ Topics
Medtechfda-clearancemedtechdry-eyemedical-deviceindication-expansion